Connect with us

Emerging Markets

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) Heats Up as DCVax®-L Proves Safe & Effective While Sawston Facility Applies for Commercial Manufacturing License for Cellular Therapies

Published

on

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) has made a significant move northbound out of the trading channel where it was trading for the past few weeks since the stock was decimated due to a massive short attack helped along by Adam Feuerstein’s misleading article on Stat News. The move up comes after the Company reported its application for license of the manufacturing facility in Sawston, UK for commercial manufacturing of cellular therapies has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA).  NWBO is targeting Glioblastoma multiforme (GBM) the deadliest, most treatment resistant cancers and the Company continue to see significant progress where all others have failed including many big names in biotech. 

NWBO is among the most exciting stocks in small caps. Recently the Company released the much-anticipated results of the Phase 3 clinical trial of DCVax®-L for GBM presented at NYAS on May 10 which showed significant improved overall survival. Patients treated with DCVax-L showed a clinically meaningful and statistically significant extension of survival, in both newly diagnosed and recurrent GBM. Primary endpoint was met (mOS in nGBM) with statistical significance, secondary endpoint met (mOS in rGBM) with statistical significance. The safety profile was excellent, with no autoimmune reactions and noteworthy long tails of survival. The stock has a significant short position that could fuel a massive short squeeze as NWBO continues to make progress. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe.  The Company has a broad platform technology for DCVax® dendritic cell-based vaccines.  Speculation is sky high that NWBO is on the verge of major success where all others have failed including many big names recently who hail DCVax®-L as an effective treatment/cure for the deadliest, most treatment resistant cancers. Glioblastoma multiforme (GBM) represents a potential market expected to reach $1.4 billion by 2025. DCVax®-L has been featured by main stream press numerous times as many recovered patients have come forward crediting DCVax®-L for saving their lives. The stock represents easily among the highest risk-reward opportunities in the market today.  

NWBO lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.”  This Phase III trial has been completed and the top line data was presented by a key investigator at a recent scientific meeting. The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers.  It has completed a 40-patient Phase I trial and plans to prepare for Phase II trials as resources permit. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.  

Northwest has an integrated strategy for protection of its technology through both patents and other mechanisms, such as Orphan Drug status. Currently the Company holds 204 issued patents and 65 pending patent applications worldwide, grouped into 11 patent families. Of these, 191 issued patents and 52 pending patent applications directly relate to its DCVax products. In the United States and Europe, some of its patents and applications relate to compositions and the use of products, while other patents and applications relate to other aspects such as manufacturing and quality control. Additionally, with the acquisition of Flaskworks, Northwest gained ownership of a portfolio of patents and patent applications which include those held by Flaskworks as well as patents and patent applications exclusively licensed by Flaskworks from Northeastern University. The portfolio includes a total of thirteen patent families, with issued patents and pending applications worldwide. Collectively these patents and patent applications cover key aspects of the design and function of automated cell culture systems.   In addition to its patent portfolio, Northwet has obtained Orphan Drug designation for DCVax-L for glioma brain cancers.  

To Find out the inside Scoop on NWBO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

NWBO

On July 6 NWBO reported an application for license of the manufacturing facility in Sawston, UK for commercial manufacturing of cellular therapies has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA).  The application builds upon the 3 licenses received for the Sawston facility in 2021. This application for a Manufacturer’s license (MIA) represents the culmination of an additional year of intensive work, beyond the preparations over more than 2 years that were required for the applications for the initial licenses last year.  The first license was received in September, 2021, from the Human Tissue Authority of the UK, and provided authorization for collection and storage of human tissues (such as the tumor tissue used to make the lysate for DCVax®-L products) and cells (such as the immune cells used to make DCVax-L).  The second and third licenses were received in December, 2021, from MHRA, and provided authorization for manufacturing cellular therapies for use in clinical trials and compassionate use (“Specials”) cases, respectively.   

As reported last year, a further license from MHRA is required specifically for commercial manufacturing of cellular products. Application for a commercial license requires meeting even higher standards. Preparations for this commercial license have included the creation of a further 50 standard operating procedures (SOPs) and policy and technical specification documents, validation of transport and shipping, and full validation and qualification of seven new pieces of equipment.  Each step in such validation and qualification processes incorporates user requirement specification, design qualification, installation/operational qualification and performance qualification.  This takes many months for each item of equipment.  Additional controlled rate freezers were also procured, validated and qualified to expand the cryostorage capacity at the Sawston facility. 

An automated system for the fill and finish of DCVax-L product has also been delivered, installed, validated and qualified.  “Fill and finish” is the final step of the process, after a batch of DCVax-L product has been manufactured, in which the batch is allocated into single doses in individual vials for cryopreservation and distribution. Preparations for this commercial license application have also included successful recruitment of additional highly experienced, senior-level GMP experts and scientists.  There is a significant shortage of such senior experts throughout the cell and gene therapy sector, and such personnel are in extreme demand.  These additions bring significant additional capacity and depth to the Sawston team. 

As was the case before, the preparations for this license application have taken place in the context of ongoing supply chain problems, personnel shortages and other post-COVID obstacles.  For example, delivery of necessary equipment has been delayed months beyond the scheduled delivery dates.  Certain reagents that are required ingredients for DCVax-L have been subject to ongoing supply shortages, and there is an ongoing worldwide shortage of the special caps required for the cell culture flasks used to make DCVax-L.  The cumulative effects of these and other individual delays and shortages have been, and continue to be, substantial. 

The next step for this license application will be another on-site inspection of the Sawston facility by MHRA – this time, inspecting the facility, its procedures, personnel, regulatory documents, capacity and capabilities in accordance with the standards for commercial manufacturing.  Following the inspection, a report of the inspection results and any findings needing any corrective action will be issued by MHRA. 

Following completion of any post-inspection actions, the Company is hopeful that a manufacturing license for commercial production of cellular products in the Sawston facility may be approved by year-end. Such a manufacturing license is separate from any regulatory decision about approval of DCVax-L itself.  The Company has not to date submitted an application for commercial approval of DCVax-L. 

Dr. Mike Scott, President of Advent Bioservices commented “Our Team has put in an extraordinary effort to meet our self-imposed, end of Q2 deadline to submit the MIA application.  The standards set for the manufacturing of commercially licensed advanced medicinal therapies are understandably extremely stringent.  We now await scrutiny of the application and processes by the MHRA, and are ready to welcome their inspectors to the Sawston facility.” 

For More on NWBO Subscribe Right Now!

Currently trading at a $750 million market valuation NWBO has over $15 million in the treasury and is fully funded moving forward. NWBO is among the most exciting stocks in small caps. Recently the Company released the much-anticipated results of the Phase 3 clinical trial of DCVax®-L for GBM presented at NYAS on May 10 which showed significant improved overall survival. Patients treated with DCVax-L showed a clinically meaningful and statistically significant extension of survival, in both newly diagnosed and recurrent GBM. Primary endpoint was met (mOS in nGBM) with statistical significance, secondary endpoint met (mOS in rGBM) with statistical significance. The safety profile was excellent, with no autoimmune reactions and noteworthy long tails of survival. The stock has a significant short position that could fuel a massive short squeeze as NWBO continues to make progress moving forward. The stock recently broke northbound out of its trading range after the Company reported its application for license of the manufacturing facility in Sawston, UK for commercial manufacturing of cellular therapies has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA).  NWBO is targeting Glioblastoma multiforme (GBM) the deadliest, most treatment resistant cancer and the Company continues to see significant progress where all others have failed including many of the biggest names in biotech. Microcapdaily first gave the heads up on NWBO on February 3, 2020 when the stock was $0.18 per share in our article: The Exciting Story of Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) We will be updating on NWBO as more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in NWBO either long or short and we have not been compensated for this article.

Emerging Markets

Is today’s surge in MMTec Inc (NASDAQ: MTC) justified ?

Published

on

MMTec, Inc. (NASDAQ: MTC) ended the day at $2.0700 with a gain of $0.5800 (+38.93%). The stock prices fluctuated between $1.4000 - $2.5299, with more than 2.98M shares exchanging hands.

MMTec, Inc. (NASDAQ: MTC) ended the day at $2.0700 with a gain of $0.5800 (+38.93%). The stock prices fluctuated between $1.4000 – $2.5299, with more than 2.98M shares exchanging hands.

So why did MTC surge today ?

The failure of Silicon Valley Bank led to a sell-off in equities and a shift to safe-haven assets, such as US Treasuries and gold. Markets have calmed down somewhat, and the worst of the equity sell-off seems to be over. However, the market anticipates that the markets will be somewhat uneasy until a better understanding of inflation is reached and what the Federal Reserve will do next week.

To Find out the inside Scoop on MTC, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Despite most investors currently avoiding the banking sector, Wall Street sees potential opportunities, particularly in regional banks. The chaos in the market has created opportunities in the industry and several banking stocks are being punished just for being a banking stock. The collapse of Silicon Valley Bank was due to its specialisation in venture-capital financing, which made it vulnerable to the higher interest rate regime of the past 12 months.

For more on MTC Subscribe Right Now!

Therfore, today’s gains in MTC seems to be more a sympathy bounce considering the overall banking sector. Earlier in March, MMTEC, Inc. (Nasdaq: MTC) declared that it will relocate its operations from Beijing to the Hong Kong Special Administrative Region, effective March 6, 2023. The Company’s subsidiary, MM Future Technology Limited, which is a Hong Kong incorporated limited company, will assume all operations previously conducted by its subsidiary, Gujia (Beijing) Technology Co., Ltd. However, Gujia will continue to carry out specific technical research and development functions. Further, the Company, through its subsidiary HC Securities (HK) Limited, and other entities, will continue to invest its human resources in asset management and securities underwriting, and other related businesses, aiming to attract global funds to invest in the Chinese market and support China’s economic growth. The Company’s new operations headquarters is located at Room 2302, 23rd Floor, FWD Financial Center, 308 Des Voeux Road Central, Sheung Wan, Hong Kong.

We will be updating on MTC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MTC.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have no position in MTC and have not been compensated for this article.

Continue Reading

Emerging Markets

Cazoo Group Ltd (CZOO) is one stock that Wall Street could be talking for day to come

Published

on

Cazoo Group Ltd (NASDAQ: CZOO) last traded at $2.62, a gain of +0.6400 (+32.32%). More than 5M shares exchanged hands compared to an average daily volume of 228K shares. Considering that the 52 week high of CZOO is more than 65$, there seems to be a lot of room to the upside.

To Find out the inside Scoop on CZOO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Why did CZOO surge last week? Welcome to the Carvana of the UK!

Cazoo, a publicly traded company (NYSE: CZOO), was founded in 2018 by serial entrepreneur Alex Chesterman OBE. The company’s mission is to revolutionize the UK’s car buying and selling experience by offering consumers better selection, value, transparency, convenience, and peace of mind. Cazoo’s goal is to make the car buying or selling process as simple as purchasing any other product online. The company enables customers to buy, sell, or finance a car entirely online, with delivery or collection available in as little as 72 hours.

Recently, Cazoo Group Ltd, the UK’s leading online car retailer, updated its business performance and progress with the restructuring announced in January. The CEO, Alex Chesterman, expressed satisfaction with the progress made so far in 2023, despite the challenging economic environment. The company has taken swift and decisive management action to restructure the group, improve unit economics, and reduce fixed costs. The rightsizing of headcount and operational footprint is well underway, and the company expects to complete the restructuring before the end of Q1 2023. The company has seen significant improvement in its GPU, with retail GPU tracking at approximately £900, up from £600 in Q4 2022. Cazoo has sold over 100,000 cars entirely online in the UK in the three years since its launch. The company remains fully focused on driving higher profitability and has appointed Jonathan Dunkley as Chief Operating Officer. Cazoo’s cash reserves remain strong, and the company expects to achieve profitability without external funding until H2 2024. The company expects to end 2023 with over £100m of cash and cash equivalents on its balance sheet and sell 40,000-50,000 UK retail units in the current year.

For more on CZOO, Subscribe Right Now!

The online car market in the UK has been growing rapidly in recent years, driven by increasing consumer demand for convenience and transparency in the car buying process. Online car retailers such as Cazoo, Carzam, and Cinch have emerged as major players in the market, offering a wide selection of used cars for sale online with home delivery or pickup options. These companies use advanced technology to provide customers with a seamless buying experience, including virtual vehicle inspections, transparent pricing, and easy financing options. The COVID-19 pandemic has further accelerated the shift towards online car buying as consumers seek to avoid in-person interactions and dealerships adapt to new ways of doing business.

So if CZOO learns from Carvana’s mistake, there is little to no doubt that CZOO could be the talk of the town in days to come. We will be updating on CZOO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CZOO.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CZOO, either long or short, and we have not been compensated for this article

Continue Reading

Emerging Markets

Ocean Biomedical Stock Surge could just be getting started and here’s why

Published

on

Shares of Ocean Biomedical (NASDAQ:OCEA) surged more than 100% on Thursday, following a talk by the company’s scientific co-founder, Dr. Jack A. Elias, at Brown University’s Legorreta Cancer Center. The preclinical-stage biotech, which went public on the NASDAQ on February 15, focuses on developing novel treatments for deadly diseases, including malaria, multiple cancers, and pulmonary fibrosis.

During the talk, Dr. Elias presented exciting details about potential therapies to suppress tumors in various cancers, focusing on the company’s work in understanding the role of the protein Chitinase 3-like-1 (CHI3LI) in the progression of lung cancer. He also discussed his discoveries on how certain monospecific and bispecific antibodies can be used as therapies to treat non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). The company aims to expedite these findings into phase 1 trials.

To Find out the inside Scoop on OCEA, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The excitement over this preliminary news stems from the large target groups for both diseases. According to Cancer.net statistics, NSCLC is the leading cause of cancer death and the second-most diagnosed cancer in the US, affecting around 236,740 people. GBM is the most common primary brain tumor in adults, with an average survival period of just 15 months and no cure.

The recent surge in Ocean Biomedical’s shares also comes on the heels of an announcement on February 28 that co-founder Dr. Jonathan Kurtis had been awarded a patent for the discovery of the third parasite target PfCDPK-5. This target has the potential to be used to halt the malaria parasite in various stages of its cycle, opening up new possibilities for treating this deadly disease.

Ocean Biomedical’s focus on developing novel treatments for deadly diseases and its recent exciting findings have generated significant investor interest. However, it is important to note that investing in preclinical-stage biotech companies carries a high level of risk. There is no guarantee that these discoveries will translate into effective treatments or that the company will receive regulatory approval.

For more on OCEA Subscribe Right Now!

Nevertheless, the positive developments from Ocean Biomedical are a significant milestone and hold great promise for patients suffering from deadly diseases such as cancer and malaria. If the company’s discoveries prove successful in further clinical trials, they could potentially generate significant revenue and transform the standard of care for these diseases. We will be updating on OCEA when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with OCEA.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in OCEA, either long or short, and we have not been compensated for this article

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.